Endothelial dysfunction and systemic inflammation in persons with echolucent carotid plaques

Summary

Echolucent carotid plaques are associated with high risk for future ischemic cerebrovascular events independent of the degree of stenosis. Elevated levels of markers of systemic inflammation and endothelial dysfunction are predictors for future myocardial infarction and stroke.The present study was undertaken to investigate the relations between plaque morphology, endothelial dysfunction assessed by tissue-plasminogen activator antigen (t-PA ag) and von Willebrand factor (vWF), and systemic inflammation in persons with carotid stenosis.We conducteda crosssectional study including 133 persons with carotid stenosis and 138 controls without stenosis recruited from the populationbased Tromsø Study. High-resolution B-mode and colour Doppler/pulsed-wave Doppler ultrasonography of both carotid arteries was performed, and plaque morphology in terms of echogenicity was assessed. Persons with carotid stenosis had significantly higher plasma t-PA and vWF concentrations than controls. There was a significant inverse relationship between t-PA ag and plaque echogenicity (p=0.034).The increased plasma t-PA ag in persons with carotid stenosis was not associated with increased plasminogen activator inhibitor-I (PAI-1).Persons with echolucent carotid plaques had higher degree of systemic inflammation, and plasma t-PA and vWF concentration increased significantly across quartiles of WBC, fibrinogen, and hs-CRP. Our findings may suggest that plasma t-PA may be superior to vWF asa marker for endothelial dysfunction due to its ability to discriminate between various plaque echogenicity, and that the predictive role of t-PA ag in cardiovascular disease is independent of inhibited fibrinolysis.

Keywords

Atherosclerosis - ultrasound / diagnosis - von Willebrand factor - plasminogen activators - cerebrovascular disease

Footnote: Jean Amiral and Anne Marie Vissac are share-holders in Hyphen BioMed which produces and sells some of the kits used.

• References

• 1 European Carotid Plaque Study Group. Carotid artery plaque composition--relationship to clinical presentation and ultrasound B-mode imaging. Eur J Vasc Endovasc Surg 1995; 10: 23-30.
• 2 Mathiesen EB, Bonaa KH, Joakimsen O. Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: the tromso study. Circulation 2001; 103: 2171-5.
• 3 Cines DB, Pollak ES, Buck CA. et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
• 4 Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist?. Br J Haematol 1995; 90: 244-8.
• 5 Felmeden DC, Blann AD, Spencer CG. et al. A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Blood Coagul Fibrinolysis 2003; 14: 425-31.
• 6 Lee KW, Lip GY, Tayebjee M. et al. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005; 105: 526-32.
• 7 Ferro D, Pittoni V, Quintarelli C. et al. Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. Circulation 1997; 95: 1425-32.
• 8 Romano M, Pomilio M, Vigneri S. et al. Endothelial perturbation in children and adolescents with type 1 diabetes: association with markers of the inflammatory reaction. Diabetes Care 2001; 24: 1674-8.
• 9 Hansen JB, Svensson B, Zhang CL. et al. Basal plasma concentration of tissue plasminogen activator (t-PA) and the adaption to strenuous exercise in familial hypercholesterolaemia (FH). Blood Coagul Fibrinolysis 1994; 05: 781-7.
• 10 Hellsten G, Boman K, Bjerle P. et al. Increased plasminogen activator inhibitor and tissue plasminogen activator levels in subjects with electrocardiographic abnormality indicative of ischaemic heart disease: a cross-sectional study in Norsjo, Sweden. Eur Heart J 1992; 13: 57-60.
• 11 Hamsten A, Wiman B, de FU. et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
• 12 Margaglione M, Di MG, Grandone E. et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb 1994; 14: 1741-5.
• 13 Lindgren A, Lindoff C, Norrving B. et al. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 1996; 27: 1066-71.
• 14 Thompson SG, Kienast J, Pyke SD. et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.N Engl J Med 1995; 332: 635-41.
• 15 Folsom AR, Rosamond WD, Shahar E. et al. Prospective study of markers of hemostatic function with risk of ischemic stroke The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999; 100: 736-42.
• 16 Futterman LG, Lemberg L. Inflammation in plaque rupture: an active participant or an invited guest?. AmJ Crit Care 1998; 07: 153-61.
• 17 Alvarez GB, Ruiz C, Chacon P. et al. High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. J Vasc Surg 2003; 38: 1018-24.
• 18 Maresca G, Di BA, Marchioli R. et al. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19: 1368-77.
• 19 Cleland SJ, Sattar N, Petrie JR. et al. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 2000; 98: 531-5.
• 20 Mathiesen EB, Joakimsen O, Bonaa KH. Prevalence of and risk factors associated with carotid artery stenosis: the Tromso Study. Cerebrovasc Dis 2001; 12: 44-51.
• 21 Mathiesen EB, Joakimsen O, Bonaa KH. Intersonographer reproducibility and intermethod variability of ultrasound measurements of carotid artery stenosis: The Tromso Study. Cerebrovasc Dis 2000; 10: 207-13.
• 22 Gray-Weale AC, Graham JC, Burnett JR. et al. Carotid artery atheroma: comparison of preoperative B-mode ultrasound appearance with carotid endarterectomy specimen pathology. J Cardiovasc Surg (Torino) 1988; 29: 676-81.
• 23 Joakimsen O, Bonaa KH, Stensland-Bugge E. Reproducibility of ultrasound assessment of carotid plaque occurrence, thickness, and morphology The Tromso Study. Stroke 1997; 28: 2201-7.
• 24 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
• 25 Nordoy A, Hansen JB, Brox J. et al. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutr Metab Cardiovasc Dis 2001; 11: 7-16.
• 26 Juhan-Vague I, Pyke SD, Alessi MC. et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057-63.
• 27 Hoffmeister HM, Jur M, Helber U. et al. Correlation between coronary morphology and molecular markers of fibrinolysis in unstable angina pectoris. Atherosclerosis 1999; 144: 151-7.
• 28 Rodgers GM. Hemostatic properties of normal and perturbed vascular cells. FASEB J 1988; 02: 116-23.
• 29 Ridker PM, Hennekens CH, Stampfer MJ. et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-3.
• 30 Ridker PM, Vaughan DE, Stampfer MJ. et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.
• 31 Sporn LA, Chavin SI, Marder VJ. et al. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest 1985; 76: 1102-6.
• 32 Kenagy RD, Vergel S, Mattsson E. et al. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler Thromb Vasc Biol 1996; 16: 1373-82.
• 33 Lupu F, Heim DA, Bachmann F. et al. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 1444-55.
• 34 Kluft C, Jie AF, Rijken DC. et al. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemost 1988; 59: 329-32.
• 35 Eliasson M, Jansson JH, Nilsson P. et al. Increased levels of tissue plasminogen activator antigen in essential hypertension A population-based study in Sweden. J Hypertens 1997; 15: 349-56.
• 36 Yamagami H, Kitagawa K, Nagai Y. et al. Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques. Stroke 2004; 35: 677-81.
• 37 Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.